Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Angle granted European patent for CellKeep, US patent imminent
(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application. The AIM-traded firm said the CellKeep slide, developed over three years, addresses the prevalent issue of circulating tumour cell (CTC) loss in standard laboratory microscopy techniques for cytological analysis.
Through in-house testing, the proprietary slide demonstrated an impressive elimination of over 70% of CTC loss associated with conventional techniques.
The board said the breakthrough was significant as it enhanced the efficiency of the 'Parsortix' system, which captures intact and viable CTCs from blood for downstream analysis.
By minimising cell loss during the transfer of CTCs to microscope slides and preserving cell morphology, the CellKeep slide ensured higher sample positivity rates and better preservation of CTC morphology and clusters.
Moreover, the company said the use of CellKeep slides reduced costs by concentrating CTCs into a smaller area on the slide, limiting the quantity of high-cost antibodies and imaging time required for analysis.
Angle said the CellKeep slide was an integral component of its 'Portrait+' CTC staining kit, providing customers with enhanced capabilities to identify and enumerate CTCs harvested using the Parsortix system.
"We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions," said chief executive officer Andrew Newland.
"Following harvesting of rare CTCs from patient blood samples using the Parsortix system, the CellKeep slide and associated methodology will significantly improve the capture of CTCs for microscopy-based biomarker assays and will enhance sensitivity across Angle's assay portfolio.
"This is a significant technology advancement for the CTC liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer."
At 0919 BST, shares in Angle were up 8.33% at 13p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.